美沙拉嗪肠溶片联合康复新液治疗溃疡性结肠炎的疗效探讨

Therapeutic Effect of Mesalazine Enteric-coated Tablets Combined with Rehabilitation New Liquid on Ulcerative Colitis

目的探讨美沙拉嗪肠溶片联合康复新液治疗溃疡性结肠炎的疗效。方法选取该院2015年1月—2018年6月收治的溃疡性结肠炎患者96例为对象进行研究,采用双盲随机法将其随机分为观察组和对照组,各48例。采用美沙拉嗪肠溶片治疗对照组,在此基础上联合康复新液治疗观察组。观察比较两组治疗前后Sutherland指数变化、疗效、不良反应及随访6个月复发情况。结果两组治疗前Sutherland指数比较差异无统计学意义(P>0.05);而治疗后观察组Sutherland指数较对照组明显降低,差异有统计学意义(t=2.257 3,P=0.030)。观察组治疗有效率95.83%较对照组83.33%明显较高,差异有统计学意义(χ~2=8.369 7,P=0.003)。两组治疗期间均未发生任何不良反应。随访6个月,观察组复发率为10.42%较对照组25.00%显著较低,差异有统计学意义(χ~2=7.293 2,P=0.006)。结论针对溃疡性结肠炎患者采用美沙拉嗪肠溶片联合康复新液的疗效非常显著,既能显著改善患者各种症状,且无不良反应,又能减少患者疾病复发,因此值得临床应用推广。

Objective To investigate the efficacy of mesalazine enteric-coated tablets combined with Kangfuxin solution in the treatment of ulcerative colitis. Methods 96 patients with ulcerative colitis admitted to our hospital from January2015 to June 2018 were enrolled in the study. They were randomly divided into observation group and control group, 48 cases each. The control group was treated with mesalazine enteric-coated tablets, and the observation group was treated with Kangfuxin solution. The Sutherland index changes, efficacy, adverse reactions and recurrence at 6 months followup were compared between the two groups. Results There was no significant difference in the Sutherland index between the two groups before treatment was not statistically significant(P>0.05). The Sutherland index of the observation group was significantly lower than that of the control group, the difference was statistically significant(t=2.257 3, P=0.030).The effective rate of treatment in the observation group was 95.83%, which was significantly higher than that in the control group(83.33%), and the difference was statistically significant(χ^2=8.369 7, P=0.003). No adverse reactions occurred during the two treatment periods. After 6 months of follow-up, the recurrence rate of the observation group was10.42%, which was significantly lower than that of the control group25.00%, and the difference was statistically significant(χ^2=7.293 2, P=0.006). Conclusion The efficacy of mesalazine enteric-coated tablets combined with rehabilitation new fluid in patients with ulcerative colitis is very significant, which can significantly improve various symptoms of patients, and has no adverse reactions, and can reduce the recurrence of disease, so it is worthy of clinical application.